beta-Adrenergic receptor polymorphisms and response to salmeterol.

Area of Science:

• Pharmacogenomics
• Respiratory Medicine
• Asthma Treatment

Background:

• Patients with asthma homozygous for arginine at the B16 position of the beta2-adrenergic receptor may not respond well to short-acting beta-agonists.
• This study investigates if this genotype-specific effect extends to long-acting beta-agonists and is influenced by concurrent inhaled corticosteroid (ICS) use.

Purpose of the Study:

• To determine if asthma patients with the B16Arg/Arg genotype exhibit altered responses to salmeterol compared to B16Gly/Gly individuals.
• To assess whether concurrent inhaled corticosteroid (ICS) use modifies the response to salmeterol in B16Arg/Arg asthma patients.

Main Methods:

• Two cohorts of asthma patients were studied: those homozygous for arginine at B16 (B16Arg/Arg) and those homozygous for glycine at B16 (B16Gly/Gly).
• In cohort 1, patients received salmeterol and discontinued ICS. In cohort 2, patients received salmeterol while continuing ICS.
• Salmeterol response was compared between genotypes in both cohorts.

Main Results:

• In both cohorts, B16Arg/Arg subjects showed no benefit from salmeterol compared to B16Gly/Gly subjects.
• In cohort 1 (salmeterol without ICS), B16Arg/Arg subjects had significantly lower peak expiratory flow (PEF) compared to B16Gly/Gly subjects.
• In cohort 2 (salmeterol with ICS), B16Arg/Arg subjects experienced lower PEF, reduced FEV1, increased symptom scores, and higher rescue medication use compared to B16Gly/Gly subjects.

Conclusions:

• Asthma patients with the B16Arg/Arg genotype may have an impaired therapeutic response to salmeterol, irrespective of whether ICS are used concurrently.
• Further investigation into alternative asthma treatment strategies is warranted for B16Arg/Arg patients.